Literature DB >> 12048741

Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia.

Ahmed Aboraya1, Jennifer Schumacher, Ehab Abdalla, James LePage, Melanie McGhee, Deborah Butcher, Holly Griffin, Mohammed Shahda.   

Abstract

This case report describes an 18-year-old African American male who presented to a state psychiatric facility with symptoms of bizarre behavior, delusions and auditory hallucination. He was diagnosed with schizophrenia and treated with eight days of risperidone followed by five days of olanzapine. During this two-week period, this patient began to develop signs and symptoms of neuroleptic malignant syndrome (NMS). Two weeks after all neuroleptic medications were discontinued, all his vital signs and labs returned to baseline. This case report and others from literature suggest that risperidone and olanzapine may induce NMS in some patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12048741

Source DB:  PubMed          Journal:  W V Med J        ISSN: 0043-3284


  3 in total

Review 1.  Children with schizophrenia: clinical picture and pharmacological treatment.

Authors:  Gabriele Masi; Maria Mucci; Cinzia Pari
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 3.  Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review.

Authors:  Rachel Neuhut; Jean-Pierre Lindenmayer; Raul Silva
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-08       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.